wide
rang
respiratori
virus
identifi
caus
signific
morbid
mortal
among
transplant
recipi
includ
influenza
respiratori
syncyti
viru
rsv
parainfluenza
viru
piv
rhinoviru
human
metapneumoviru
hmpv
coronaviru
tabl
sever
featur
common
among
virus
transplant
popul
season
respiratori
viral
infect
among
transplant
recipi
usual
follow
gener
virus
caus
rang
diseas
mild
congest
rhinorrhea
sever
tracheobronch
bronchiol
pneumonia
one
viru
exclus
associ
one
clinic
syndrom
ie
ill
croup
etc
diagnost
strategi
initi
broad
attempt
screen
recogn
particular
emphasi
one
might
amen
therapytranspl
recipi
often
present
mild
atyp
symptom
fever
may
absent
lung
transplant
recipi
exampl
may
initi
subject
symptom
short
breath
subtl
chang
pulmonari
function
test
without
typic
viral
shed
usual
prolong
among
transplant
recipi
prolong
shed
seen
even
use
antivir
therefor
may
contribut
increas
risk
resist
variant
transplant
recipi
higher
risk
infecti
complic
compar
immunocompet
host
respiratori
viral
infect
signific
risk
factor
subsequ
develop
fungal
bacteri
respiratori
viral
infect
appear
risk
factor
acut
chronic
reject
greatest
risk
lung
transplant
although
data
topic
literatur
pathogenesi
link
respiratori
viral
infect
reject
clearli
understoodpediatr
solid
organ
lung
transplant
recipi
appear
greatest
risk
respiratori
viral
infect
sever
cours
recent
retrospect
observ
cohort
pediatr
solid
organ
transplant
recipi
found
death
respiratori
viral
infect
rare
definit
attribut
death
potenti
nosocomi
pathogen
spread
staff
visitor
mild
upper
respiratori
ill
asymptomat
nosocomi
transmiss
influenza
transplant
ward
associ
signific
mortalitymorbid
earli
sinc
one
clinic
distinguish
diseas
caus
respiratori
virus
diagnosi
use
broad
rang
techniqu
consid
particularli
earli
period
transplant
augment
immunosuppress
respiratori
viral
season
particularli
among
lung
transplant
recipi
gener
patient
presum
respiratori
viral
infect
nasopharyng
swab
wash
aspir
perform
sent
test
upper
tract
sampl
fail
document
caus
respiratori
ill
clinic
radiolog
evid
lower
tract
involv
bronchoalveolar
lavag
consid
sent
rang
avail
test
wide
rang
assay
detect
respiratori
virus
commerci
avail
mani
center
local
develop
assay
detect
select
virus
nucleic
acid
amplif
assay
appear
sensit
diagnost
tool
avail
allow
simultan
detect
broad
rang
respiratori
pathogen
singl
sampl
therefor
prefer
diagnost
test
method
immunocompromis
multiplex
pcr
assay
provid
advantag
identif
virus
routin
found
convent
method
includ
rhinoviru
although
multiplex
affect
sensit
assay
commerci
avail
multiplex
assay
differ
sensit
specif
differ
virus
notabl
clinician
awar
perform
characterist
assay
use
influenza
pcr
assay
distinguish
among
viral
subtyp
quantifi
viral
load
although
avail
center
rapid
assay
allow
rapid
result
within
hour
particularli
influenza
rsv
although
sensit
may
vari
among
viru
rapid
antigen
detect
avail
influenza
rsv
advantag
rapid
result
test
within
suboptim
sensit
low
predict
sever
studi
direct
fluoresc
antibodi
dfa
test
primari
patient
specimen
document
sensit
approach
pcr
certain
dfa
test
limit
lack
reagent
virus
rhinoviru
coronaviru
serolog
use
diagnosi
acut
infect
use
epidemiolog
studi
case
influenza
although
sot
recipi
might
respond
antibodi
wane
quickli
even
infect
final
although
viral
cultur
previous
consid
prefer
diagnost
test
current
use
routin
clinic
practic
patient
presum
respiratori
viral
infect
nasopharyng
swab
wash
aspir
perform
sent
test
strong
low
case
diagnost
uncertainti
especi
clinic
radiolog
evid
lower
tract
involv
bronchoalveolar
lavag
sent
rang
avail
test
strong
low
influenza
viru
orthomyxoviru
associ
signific
morbid
mortal
winter
season
immunocompet
immunocompromis
patient
three
main
viral
strain
associ
human
infect
name
influenza
influenza
influenza
b
new
strain
influenza
come
reassort
anim
human
virus
caus
global
subsequ
replac
prior
season
influenza
viru
also
two
differ
strain
influenza
b
viru
yamagata
victoria
jointli
circul
last
influenza
season
clinic
present
influenza
transplant
recipi
similar
gener
popul
fever
patient
cough
rhinorrhea
common
symptom
report
recent
larg
howev
risk
complic
influenza
appear
higher
sot
recipi
compar
gener
popul
particularli
incid
pneumonia
transplant
recipi
allograft
dysfunct
acut
reject
observ
sever
case
studi
observ
excess
morbid
mortal
sot
recipi
compar
gener
popul
rate
report
sever
influenza
vari
admiss
icu
attribut
mortal
estim
ascertain
bias
toward
inclus
patient
sever
diseas
may
howev
overestim
sever
influenza
sot
recipi
risk
factor
sever
influenza
sot
recipi
includ
use
antilymphocyt
globulin
diabet
mellitu
pneumonia
bacteri
fungal
earli
infect
month
nosocomi
acquisit
influenza
describ
risk
factor
admiss
use
influenza
vaccin
earli
antivir
therapi
consist
associ
reduc
rate
complic
pneumonia
admiss
icu
use
invas
ventil
death
see
patient
known
suspect
influenza
isol
patient
standard
droplet
precaut
influenza
vaccin
key
measur
prevent
two
type
influenza
vaccin
exist
inactiv
influenza
vaccin
intranas
influenza
vaccin
laiv
laiv
contraind
sot
recipi
close
contact
due
potenti
risk
dissemin
vaccin
strain
one
dose
season
intramuscular
trival
quadrival
influenza
vaccin
standard
care
adult
two
dose
week
apart
recommend
children
year
immunogen
influenza
vaccin
variabl
sot
recipi
depend
type
organ
immunosuppress
regimen
use
composit
howev
increas
data
report
benefici
effect
influenza
vaccin
sot
recipi
lung
transplant
recipi
vaccin
adjuv
influenza
vaccin
associ
reduc
incid
subsequ
influenza
infect
vs
unvaccin
patient
influenza
vaccin
also
associ
lower
risk
graft
loss
death
kidney
transplant
even
vaccin
patient
develop
influenza
reduct
sever
diseas
viral
load
nasopharyng
swab
compar
unvaccin
patient
previou
vaccin
associ
lower
risk
pneumonia
icu
stay
larg
cohort
sot
hematopoiet
stem
cell
transplant
hsct
influenza
vaccin
therefor
highli
recommend
sot
recipi
household
influenza
vaccin
well
toler
sot
recipi
advers
event
vaccin
usual
mild
short
recent
random
control
trial
found
increas
immunogen
sot
recipi
use
vaccin
booster
strategi
use
two
dose
standard
dose
vaccin
week
approach
particularli
use
case
expect
lower
respons
vaccin
due
enhanc
immunosuppress
reader
refer
american
societi
transplant
vaccin
guidelin
seri
detail
discuss
influenza
vaccin
antivir
prophylaxi
oseltamivir
may
altern
influenza
vaccin
case
expect
diminish
respons
vaccin
random
control
trial
transplant
recipi
found
prophylaxi
case
close
contact
patient
document
influenza
sot
recipi
may
receiv
postexposur
prophylaxi
particularli
case
high
risk
complic
nosocomi
influenza
earli
lung
transplant
recipi
therapi
reject
two
famili
drug
approv
treatment
influenza
name
inhibitor
neuraminidas
inhibitor
amantadin
rimantadin
activ
influenza
b
high
incid
antivir
resist
influenza
drug
longer
recommend
treatment
neuraminidas
inhibitor
includ
oral
oseltamivir
inhal
zanamivir
intraven
peramivir
tabl
laninamivir
inhal
neuraminidas
inhibitor
approv
japan
prophylaxi
treatment
intraven
form
zanamivir
avail
europ
investig
drug
current
approv
none
drug
specif
test
prospect
trial
sot
recipi
therapi
influenza
studi
shown
earli
treatment
oseltamivir
associ
decreas
mortal
admiss
icu
complic
outcom
sot
less
data
avail
inhal
zanamivir
appear
equal
effect
experi
iv
zanamivir
sot
recipi
intraven
peramivir
approv
use
singl
dose
repeat
dose
andor
step
oral
oseltamivir
may
necessari
sot
therapi
neuraminidas
inhibitor
may
associ
reduc
incid
allograft
dysfunct
lung
transplant
given
benefici
effect
earli
administr
antivir
drug
oseltamivir
zanamivir
therapi
start
empir
patient
symptom
compat
influenza
microbiolog
confirm
baloxavir
therapi
influenza
novel
mechan
action
inhibit
endonucleas
baloxavir
shown
efficaci
treat
uncompl
influenza
healthi
subject
howev
data
use
transplant
recipi
transplant
recipi
known
prolong
viral
replic
decis
continu
antivir
therapi
beyond
standard
treatment
cours
gener
depend
whether
patient
persist
clinic
symptom
monitor
viral
replic
nasopharyng
swab
pcr
help
guid
infect
control
practic
although
gener
use
guid
durat
antivir
although
earli
hour
administr
antivir
associ
better
outcom
patient
may
still
benefit
therapi
irrespect
durat
symptom
sever
case
doubl
dose
ie
mg
oseltamivir
twice
day
normal
kidney
function
recommend
expert
anecdot
case
posit
outcom
sot
recipi
report
howev
larg
random
control
trial
find
benefit
use
oseltamivir
influenza
gener
importantli
pharmacokinet
studi
observ
clinic
relev
interact
oseltamivir
immunosuppress
drug
tacrolimu
cyclosporin
mycophenol
use
intraven
drug
peramivir
zanamivir
consid
case
infect
concern
oral
absorpt
although
mention
experi
drug
sot
recipi
use
amantadin
rimantadin
treatment
influenza
longer
recommend
due
high
rate
resist
drug
rate
oseltamivir
resist
high
influenza
viru
antivir
resist
occasion
describ
new
influenza
immunosuppress
exposur
oseltamivir
risk
factor
develop
antivir
resist
virus
patient
expos
oseltamivir
caus
mutat
result
increas
peramivir
retain
zanamivir
commerci
avail
resist
assay
detect
mutat
may
occur
particularli
agent
oseltamivir
use
influenza
b
treat
resist
neuraminidas
inhibitor
uncommon
influenza
influenza
b
virus
test
antivir
resist
indic
case
persist
clinic
symptom
andor
viral
shed
despit
appropri
antivir
therapi
resist
pattern
may
chang
affect
recommend
antivir
strategi
import
regularli
consult
nation
health
author
updat
recommend
transplant
recipi
receiv
antivir
therapi
neuraminidas
inhibitor
either
oseltamivir
inhal
zanamivir
influenza
suspect
strong
moder
although
earli
hour
administr
antivir
associ
better
outcom
symptomat
patient
receiv
antivir
therapi
irrespect
durat
symptom
onset
strong
low
durat
antivir
therapi
least
day
antivir
therapi
may
prolong
case
persist
clinic
symptom
weak
low
doubl
dose
oseltamivir
may
consid
sever
case
case
insuffici
respons
therapi
weak
low
iv
drug
peramivir
zanamivir
also
use
select
case
intub
patient
concern
oral
absorpt
weak
low
resist
test
consid
clinic
symptom
andor
viral
shed
present
despit
antivir
therapi
rsv
paramyxoviru
genu
pneumoviru
caus
season
annual
epidem
worldwid
diseas
seen
tropic
year
age
virtual
children
experienc
primari
infect
occur
throughout
life
risk
factor
sever
diseas
organ
transplant
includ
lung
transplant
infect
children
year
age
underli
lung
earli
acquisit
rsv
transplant
augment
immunosuppress
associ
increas
sever
diseas
transmiss
occur
contact
contamin
secret
includ
exposur
droplet
fomit
patient
known
suspect
rsv
isol
patient
use
standard
contact
prophylaxi
human
monoclon
antibodi
palivizumab
shown
effect
infant
children
month
specif
underli
updat
recommend
regard
use
publish
american
academi
pediatr
specif
recommend
given
immunocompromis
individu
except
children
younger
month
profoundli
immunocompromis
rsv
season
may
consid
prophylaxi
survey
data
suggest
prophylaxi
commonli
use
among
pediatr
transplant
howev
studi
conduct
evalu
use
solid
organ
transplant
set
cost
adult
signific
approv
vaccin
prevent
rsv
although
variou
vaccin
formul
develop
ribavirin
nucleosid
analog
activ
rsv
aerosol
form
current
drug
treatment
lower
respiratori
tract
diseas
certain
oral
iv
prepar
also
avail
use
corticosteroid
immunomodul
includ
immunoglobulin
ivig
longer
avail
palivizumab
investig
adjunct
therapi
consensu
treatment
rsv
solid
organ
transplant
recipi
remain
unsettl
howev
random
trial
popul
wide
variat
approach
lung
recipi
usual
treat
upper
lower
respiratori
tract
infect
recipi
lower
respiratori
infect
may
also
treat
upper
respiratori
infect
gener
comprehens
review
manag
rsv
infect
adult
hsct
recipi
show
patient
treat
ribavirin
regardless
form
durat
therapi
addit
immunomodul
palivizumab
ivig
rate
progress
upper
respiratori
lower
respiratori
infect
much
lower
patient
receiv
form
rsv
therapi
mortal
rate
also
lower
treat
patient
lower
respiratori
also
report
trend
toward
better
outcom
progress
lower
respiratori
infect
death
among
patient
treat
aerosol
ribavirin
immunomodul
treat
aerosol
ribavirin
publish
studi
symptomat
lung
transplant
recipi
report
improv
outcom
treat
rsv
summar
recent
includ
iv
ribavirin
plu
oral
ribavirin
plu
oral
iv
regimen
inhal
ribavirin
plu
methylprednisolon
ivig
aerosol
ribavirin
cumbersom
expens
administ
increas
evid
although
observ
studi
efficaci
oral
ribavirin
immunocompromis
lung
transplant
oral
ribavirin
consid
especi
area
aerosol
ribavirin
avail
patient
also
receiv
corticosteroid
receiv
ivig
well
importantli
oral
ribavirin
associ
signific
toxic
includ
hemolyt
anemia
leucopenia
neuropsycholog
symptom
use
contraind
pregnanc
larg
multicent
trial
need
determin
efficaci
safeti
altern
treatment
includ
oral
ribavirin
solid
organ
transplant
recipi
presatovir
formerli
novel
oral
administ
rsv
fusion
inhibitor
investig
treatment
patient
known
suspect
rsv
isol
patient
use
standard
contact
precaut
strong
moder
prophylaxi
palivizumab
may
consid
children
month
age
profoundli
immunocompromis
rsv
season
strong
low
treatment
aerosol
oral
ribavirin
recommend
lung
transplant
recipi
upper
lower
respiratori
tract
infect
weak
moder
addit
corticosteroid
ivig
ribavirin
consid
lung
transplant
recipi
upper
lower
respiratori
tract
infect
weak
low
treatment
aerosol
oral
ribavirin
solid
organ
recipi
lower
respiratori
tract
diseas
consid
weak
low
parainfluenza
pneumoviru
four
serotyp
commonli
caus
diseas
human
type
piv
type
tend
circul
sporad
fall
winter
month
temper
area
type
occur
type
least
commonli
isol
epidemiolog
still
transmiss
occur
via
spread
direct
contact
infecti
secret
fomit
diseas
seriou
particularli
pediatr
transplant
recipi
lung
transplant
recipi
although
respiratori
virus
associ
increas
risk
progress
oblit
bronchiol
lung
transplant
recipi
associ
appear
clearest
strongest
piv
lower
tract
patient
known
suspect
piv
isol
patient
use
standard
contact
approv
vaccin
recogn
prevent
antivir
agent
although
use
ivig
ribavirin
associ
benefit
manag
piv
infect
stem
cell
transplant
recipi
ribavirin
vitro
activ
inhal
form
use
treat
lung
transplant
recipi
lower
tract
diseas
expert
also
consid
use
ivig
corticosteroid
inhal
recombin
fusion
protein
undergo
investig
treatment
piv
lower
respiratori
tract
treatment
lung
transplant
recipi
piv
lower
tract
infect
ribavirin
consid
weak
low
adjunct
therapi
ribavirin
includ
ivig
corticosteroid
may
consid
lung
transplant
recipi
weak
low
human
metapneumoviru
discov
rna
paramyxoviru
clinic
pattern
similar
rsv
signific
caus
diseas
transplant
pneumovirus
vaccin
prevent
focus
tight
infect
control
measur
includ
contact
case
report
anim
data
suggest
ribavirin
without
immunoglobulin
consid
manag
sever
case
support
care
remain
mainstay
treatment
treatment
lung
transplant
recipi
human
metapneumoviru
lower
tract
infect
ribavirin
ivig
corticosteroid
consid
weak
low
human
rhinovirus
hrv
member
picornavirida
famili
common
caus
upper
respiratori
infect
adult
children
recogn
caus
clinic
signific
diseas
transplant
recipi
fatal
case
fatal
associ
prolong
shed
minim
symptom
describ
particularli
lung
transplant
recipi
clinic
import
prolong
shed
fulli
defin
although
could
potenti
pose
threat
nosocomi
current
approv
prevent
therapeut
intervent
use
molecular
diagnost
wider
rang
respiratori
virus
isol
mani
virus
newli
recogn
variant
coronaviru
polyomavirus
wu
ki
virus
bocaviru
wide
studi
transplant
recipi
clinic
impact
fulli
sever
sometim
fatal
case
virus
immunocompromis
patient
recogn
consid
differenti
diagnosi
patient
present
sever
lower
respiratori
tract
diseas
newli
identifi
virus
challeng
diagnos
sinc
includ
routin
clinic
avail
diagnost
test
addit
optim
manag
pathogen
defin
although
respiratori
virus
increasingli
recogn
caus
morbid
mortal
transplant
recipi
still
much
learn
impact
virus
prospect
studi
use
molecular
diagnost
need
understand
true
epidemiolog
clinic
spectrum
respiratori
viral
diseas
particular
studi
consequ
infect
even
mild
asymptomat
need
particularli
import
lung
transplant
recipi
lower
tract
infect
associ
increas
risk
chronic
reject
bronchiol
obliteran
syndrom
prospect
studi
use
contemporari
molecular
diagnost
tool
includ
metagenom
also
need
defin
efficaci
cost
prevent
intervent
particularli
pediatr
popul
lung
transplant
recipi
novel
therapeut
agent
also
may
use
sot
popul
small
molecul
drug
includ
oral
rsv
entri
inhibitor
presatovir
inhal
recombin
fusion
protein
shown
promis
inhibit
piv
addit
adopt
therapi
includ
gener
piv
healthi
donor
emerg
therapeut
modal
prospect
trial
need
defin
optim
time
durat
treatment
regimen
virus
estabrook
conflict
interest
manuel
receiv
research
grant
lophiu
bioscienc
